ANGPTL4 and hypertriglyceridemia: In the current study, we determined that tacrolimus improved defects in lipid metabolism, and we presumed that these findings were the result of tacrolimus-induced activation of a specific pathway that could inhibit hypertriglyceridemia and hypercholesterolemia via circulating Angptl4.